19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
19:09 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest inhibiting NAT8L could help treat Canavan disease. In a mouse model of the disease, knockout of NAT8L decreased vacuolation of the cerebellum, swelling of Purkinje cell axons and apoptosis in the...
07:00 , Apr 25, 2016 |  BioCentury  |  Regulation

Endangered TIGER?

Comments from an FDA panel suggest there may still be a path to market for rociletinib from Clovis Oncology Inc. in NSCLC, albeit a much narrower one. But that depends on the company taking advice...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Progeria N-acetyltransferase 10 (NAT10) In vitro studies suggest inhibiting NAT10 could help treat Hutchinson-Gilford progeria syndrome (HGPS)...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA); smoothened (SMO); sonic hedgehog homolog (SHH) Studies in...
08:00 , Feb 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) N-Acetyltransferase 8 (NAT8); NAT8B Human brain tissue and cell culture studies suggest NAT8 and...
07:00 , Apr 29, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Renal disease Renal disease N-acetyltransferase 8 GCN5-related putative (NAT8); solute carrier family 7 cationic amino acid transporter y+...
07:00 , Oct 9, 2006 |  BioCentury  |  Politics, Policy & Law

Valid biomarkers

Valid biomarkers Biomarker Drug Selected label content C-kit expression Gleevec imatinib (Novartis) Gleevec inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation CYP2C19 variants Vfend voriconazole (Pfizer)...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Company News

Bayer agbio/environmental news

BAY's Bayer CropScience subsidiary (Monheim, Germany) said it identified traces of a non-commercial bioengineered rice line, LLRICE601, in commercial rice seed. LLRICE601 expresses the phosphinothricin-N-acetyltransferase (PAT), a protein that provides tolerance to glufosinate-ammonium herbicide. FDA...
07:00 , May 24, 2004 |  BC Week In Review  |  Company News

Maxygen, Pioneer Hi-Bred International Inc., Verdia Inc. other research news

Researchers published in Science the generation of enzymes exhibiting glyphosate N-acetyltransferase (GAT) activity that could be used to increase glyphosate tolerance in genetically modified crops. Enzyme efficiency was improved by nearly 4 orders of magnitude...